NDAORALFOR SUSPENSION
Approved
Dec 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
VFEND (voriconazole) by Pfizer is cytochrome p450 3a4 inhibitors [moa]. Approved for aspergillosis, candidiasis, invasive fungal infection and 2 more indications. First approved in 2003.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VFEND (voriconazole) is an oral azole antifungal that inhibits Cytochrome P450 3A4 and treats serious invasive fungal infections including aspergillosis, candidiasis, cryptococcosis, and blastomycosis. It is a foundational therapy for immunocompromised patients at high risk of life-threatening fungal disease.
LOE Approaching
Declining
VFEND spending has eroded to $10K in recent data, signaling a product in late-stage decline with minimal commercial team expansion likely.
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications (5)
Worked on VFEND at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.